Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
Unternehmens-codeALC
Name des UnternehmensAlcon AG
IPO-datumApr 09, 2019
Gegründet am2018
CEOMr. David J. Endicott
Anzahl der mitarbeiter25599
WertpapierartOrdinary Share
GeschäftsjahresendeApr 09
AddresseRue Louis d'Affry 6
StadtFRIBOURG
BörseSIX Swiss Exchange
LandSwitzerland
Postleitzahl1701
Telefon41589112222
Websitehttps://www.alcon.ch/
Unternehmens-codeALC
IPO-datumApr 09, 2019
Gegründet am2018
In den vergangenen 5 Jahren wurden insgesamt
400.00M
USD an Dividenden ausgeschüttet.
ALC.NB Final Cash Dividend of gross CHF 0.2 paid on May 05, 2022 going ex on Apr 29, 2022
ALC.NB Final Cash Dividend of gross CHF 0.1 paid on May 06, 2021 going ex on May 04, 2021